Ohr Pharmaceutical, Inc. (OHRP) financial statements (2020 and earlier)

Company profile

Business Address 700 TECHNOLOGY DRIVE
PITTSBURGH, PA 15219
State of Incorp. DE
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments810413132913
Cash and cash equivalents810413132913
Prepaid expense0000100
Other undisclosed current assets00 0   
Total current assets:911413132913
Noncurrent Assets
Property, plant and equipment0000000
Long-term investments and receivables11    0
Long-term investments11    0
Intangible assets, net (including goodwill)00815161719
Goodwill   1111
Intangible assets, net (excluding goodwill)00814151618
Prepaid expense00     
Other undisclosed noncurrent assets   0000
Total noncurrent assets:12815161719
TOTAL ASSETS:10131228294632
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2215420
Accounts payable11     
Accrued liabilities00     
Other undisclosed accounts payable and accrued liabilities  15420
Debt0000000
Other liabilities10     
Other undisclosed current liabilities     25
Total current liabilities:3315445
Noncurrent Liabilities
Liabilities, other than long-term debt   0   
Deferred compensation liability, classified   0   
Total noncurrent liabilities:   0   
Total liabilities:3315445
Stockholders' equity
Stockholders' equity attributable to parent7101123254227
Common stock0000000
Additional paid in capital393713213110910170
Accumulated deficit(32)(27)(121)(108)(84)(59)(43)
Total stockholders' equity:7101123254227
TOTAL LIABILITIES AND EQUITY:10131228294632

Income statement (P&L) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
Gross profit:  0 0  
Operating expenses(28)(26)(10)(24)(25)(18)(9)
Other undisclosed operating income (loss)(1) (4)010 
Operating loss:(29)(26)(14)(24)(25)(18)(9)
Nonoperating income (expense)(1) 1(0)(1)3(0)
Other nonoperating income (expense)(1) 1(0) 00
Interest and debt expense(0)(0)1 1(0)(0)
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)      
Loss from continuing operations before equity method investments, income taxes:(30)(26)(12)(24)(25)(15)(9)
Loss from equity method investments     (0)(0)
Other undisclosed income (loss) from continuing operations before income taxes    (1)00
Net loss:(30)(26)(12)(24)(26)(15)(9)
Other undisclosed net loss attributable to parent(0)(0)(1)    
Net loss available to common stockholders, diluted:(31)(27)(13)(24)(26)(15)(9)

Comprehensive Income ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
Net loss:(30)(26)(12)(24)(26)(15)(9)
Comprehensive loss, net of tax, attributable to parent:(30)(26)(12)(24)(26)(15)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: